Mark Pegram Selected Research

Cisplatin (Platino)

7/2016

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Pegram Research Topics

Disease

37	Breast Neoplasms (Breast Cancer) 10/2021 - 01/2002
22	Neoplasms (Cancer) 10/2021 - 01/2002
6	Disease Progression 10/2021 - 11/2009
4	Triple Negative Breast Neoplasms 10/2021 - 02/2011
4	Neoplasm Metastasis (Metastasis) 01/2021 - 08/2006
4	Diarrhea 01/2020 - 11/2009
3	Brain Neoplasms (Brain Tumor) 01/2021 - 08/2006
3	Carcinoma (Carcinomatosis) 11/2002 - 01/2002
2	Nausea 01/2020 - 11/2012
2	Vomiting 01/2020 - 11/2012
2	Thrombocytopenia (Thrombopenia) 01/2017 - 11/2012
2	Leukemia 11/2010 - 01/2010
2	Cardiotoxicity 01/2010 - 01/2003
2	Exanthema (Rash) 11/2009 - 06/2005
1	Pathologic Complete Response 10/2021
1	Circulating Neoplastic Cells 01/2020
1	Fatigue 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2019
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Metabolic Brain Diseases (Encephalopathy, Metabolic) 01/2017
1	Sepsis (Septicemia) 01/2017
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2016
1	Hypoxia (Hypoxemia) 03/2010

Drug/Important Bio-Agent (IBA)

16	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2003
8	Hormones (Hormone)IBA 10/2021 - 01/2003
8	human ERBB2 proteinIBA 10/2021 - 11/2009
6	taxaneIBA 10/2021 - 01/2003
6	Lapatinib (GW572016)FDA Link 01/2020 - 11/2009
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2002
5	ErbB Receptors (EGF Receptor)IBA 10/2019 - 06/2005
4	AnthracyclinesIBA 10/2021 - 01/2003
4	Estrogen ReceptorsIBA 10/2021 - 02/2011
4	AntibodiesIBA 01/2021 - 08/2006
4	pertuzumabIBA 01/2021 - 03/2016
4	Epidermal Growth Factor (EGF)IBA 01/2021 - 07/2006
4	Ado-Trastuzumab EmtansineIBA 01/2020 - 11/2012
4	Capecitabine (Xeloda)FDA Link 01/2020 - 11/2010
4	Pharmaceutical PreparationsIBA 07/2016 - 04/2002
4	PlatinumIBA 09/2004 - 07/2002
3	Taxoids (Taxanes)IBA 10/2021 - 11/2010
3	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 02/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 04/2002
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2017
3	Letrozole (Femara)FDA LinkGeneric 11/2011 - 11/2009
2	Estrogens (Estrogen)FDA Link 01/2021 - 11/2011
2	neratinibIBA 01/2020 - 10/2017
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 11/2009
2	Transaminases (Aminotransferases)IBA 01/2020 - 11/2012
2	Niclosamide FDA Link 07/2016 - 02/2016
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2016 - 07/2002
2	Phosphotransferases (Kinase)IBA 02/2016 - 09/2007
2	Monoclonal AntibodiesIBA 03/2008 - 07/2006
2	EnzymesIBA 01/2003 - 04/2002
2	raltitrexed (D 1694)IBA 04/2002 - 01/2002
2	NB1011IBA 04/2002 - 01/2002
2	Thymidylate SynthaseIBA 04/2002 - 01/2002
1	Radioisotopes (Radionuclides)IBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	olaparibIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	tucatinibIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Biosimilar PharmaceuticalsIBA 10/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2018
1	abemaciclibIBA 08/2018
1	palbociclibIBA 08/2018
1	ribociclibIBA 08/2018
1	Estrogen Receptor Modulators (Antiestrogen)IBA 08/2018
1	Diphosphonates (Bisphosphonates)IBA 05/2018
1	Biomarkers (Surrogate Marker)IBA 05/2018
1	Circulating Tumor DNAIBA 10/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 07/2016
1	OSM-LIF ReceptorsIBA 08/2012
1	Immunoglobulins (Immunoglobulin)IBA 11/2011
1	epitumomabIBA 11/2011
1	AntigensIBA 11/2011
1	Adenosine Triphosphate (ATP)IBA 11/2010
1	ProdrugsIBA 03/2010
1	Cytotoxins (Cytolysins)IBA 03/2010
1	Mechlorethamine (Nitrogen Mustard)FDA Link 03/2010
1	PR-104AIBA 03/2010
1	Aldo-Keto ReductasesIBA 03/2010
1	PR-104IBA 03/2010
1	Aromatase InhibitorsIBA 11/2009
1	Neoplasm Antigens (Tumor Antigens)IBA 09/2007
1	tyrosine receptor (receptor, tyrosine)IBA 09/2007
1	Complementary DNA (cDNA)IBA 08/2006
1	CarcinogensIBA 08/2006
1	Capsules (Microcapsules)IBA 08/2006
1	Insulin-Like Growth Factor Binding Protein 3IBA 07/2006
1	Growth Factor ReceptorsIBA 07/2006
1	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 07/2006

Therapy/Procedure

25	Therapeutics 10/2021 - 11/2002
11	Drug Therapy (Chemotherapy) 10/2021 - 07/2002
3	Adjuvant Chemotherapy 10/2021 - 04/2012
3	Radiotherapy 01/2021 - 07/2002
1	Precision Medicine 01/2020
1	Immunotherapy 01/2020
1	Biological Therapy 04/2014